Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
04 05 2020
04 05 2020
Historique:
received:
14
02
2020
accepted:
17
04
2020
revised:
06
04
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
5
5
2021
Statut:
epublish
Résumé
Normal karyotype in therapy-related acute myeloid leukemia (t-AML) is rare and the relative contribution of prior exposure to chemotherapy or radiotherapy to outcomes in these patients remains uncertain. We performed a retrospective study of 742 patients with newly diagnosed AML and normal karyotype (t-AML, n = 61, and non-t-AML, n = 681). Patients with t-AML were older but had a similar mutational profile compared to those with non-t-AML. Overall survival (OS) and relapse-free survival (RFS) were significantly worse for patients with t-AML (P < 0.01 and P = 0.02, respectively). Patients with t-AML had a higher cumulative incidence of death in remission (51% versus 16%, P < 0.01), but not higher cumulative incidence of relapse (42% versus 56%, respectively, P = 0.21). Both intensive induction and allogeneic hematopoietic stem cell transplantation in first remission were associated with improved OS and RFS in non-t-AML but not in t-AML. Overall, although disease biology appears similar between t-AML and non-t-AML with normal karyotype as indicated by similar risks of relapse, death in remission is the main driver of inferior outcome in t-AML. Careful therapeutic decisions are required to mitigate potential treatment-related toxicity in this rare subgroup of patients with t-AML and normal karyotype.
Identifiants
pubmed: 32366832
doi: 10.1038/s41408-020-0316-3
pii: 10.1038/s41408-020-0316-3
pmc: PMC7198507
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : UT | University of Texas MD Anderson Cancer Center (MD Anderson)
ID : CA016672
Pays : International
Références
Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016).
doi: 10.1182/blood-2016-03-643544
Granfeldt Østgård, L. S. et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J. Clin. Oncol. 33, 3641–3649 (2015).
doi: 10.1200/JCO.2014.60.0890
Kayser, S. et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 117, 2137–2145 (2011).
doi: 10.1182/blood-2010-08-301713
Kern, W., Haferlach, T., Schnittger, S., Hiddemann, W. & Schoch, C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J. Clin. Oncol. 22, 2510–2514 (2004).
doi: 10.1200/JCO.2004.99.301
Fianchi, L. et al. Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am. J. Hematol. 90, E80–E85 (2015).
doi: 10.1002/ajh.23966
Qian, Z. et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem. Biol. Interact. 184, 50–57 (2010).
doi: 10.1016/j.cbi.2009.11.025
Rowley, J. D. & Olney, H. J. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 33, 331–345 (2002).
doi: 10.1002/gcc.10040
Orazi, A. et al. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies. Mod. Pathol. 6, 521–525 (1993).
pubmed: 8248107
Cleven, A. H. G. et al. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod. Pathol. 28, 552–563 (2015).
doi: 10.1038/modpathol.2014.153
Kantarjian, H. M. et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J. Clin. Oncol. 4, 1748–1757 (1986).
doi: 10.1200/JCO.1986.4.12.1748
Schoch, C., Kern, W., Schnittger, S., Hiddemann, W. & Haferlach, T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 18, 120–125 (2004).
doi: 10.1038/sj.leu.2403187
Nardi, V. et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J. Clin. Oncol. 30, 2340–2347 (2012).
doi: 10.1200/JCO.2011.38.7340
Østgård, L. S. G. et al. Reasons for treating secondary AML as de novo AML. Eur. J. Haematol. 85, 217–226 (2010).
doi: 10.1111/j.1600-0609.2010.01464.x
Chen, Y. et al. Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor. Leuk. Lymphoma 56, 1012–1019 (2015).
doi: 10.3109/10428194.2014.946023
Rowe, J. M. Therapy of secondary leukemia. Leukemia 16, 748–750 (2002).
doi: 10.1038/sj.leu.2402456
Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T. & Christiansen, D. H. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 22, 240–248 (2008).
doi: 10.1038/sj.leu.2405078
Smith, S. M. et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102, 43–52 (2003).
doi: 10.1182/blood-2002-11-3343
Short, N. J., Rytting, M. E. & Cortes, J. E. Acute myeloid leukaemia. Lancet 392, 593–606 (2018).
doi: 10.1016/S0140-6736(18)31041-9
Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN Recommendations from an international expert panel. Blood 129, 424–447 (2017).
doi: 10.1182/blood-2016-08-733196
Jabbour, E. et al. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123, 430–439 (2017).
Pagano, L. et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann. Oncol. 16, 228–233 (2005).
doi: 10.1093/annonc/mdi051
Yanada M., Matsuo K., Emi N., Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 103,1652–1658 (2005).
Cornelissen, J. J. et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109, 3658–3666 (2007).
doi: 10.1182/blood-2006-06-025627
Koreth, J. et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301, 2349–2361 (2009).
doi: 10.1001/jama.2009.813
Stelljes, M. et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J. Clin. Oncol. 32, 288–296 (2014).
doi: 10.1200/JCO.2013.50.5768
Litzow, M. R. et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 115, 1850–1857 (2010).
doi: 10.1182/blood-2009-10-249128
DiNardo, C. D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7–17 (2019).
doi: 10.1182/blood-2018-08-868752
Wei, A. H. et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J. Clin. Oncol. 37, 1277–1284 (2019).
doi: 10.1200/JCO.18.01600